Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
15
% (as a percentage of net assets for the immediately preceding consolidated fiscal year and the immediately preceding fiscal year; less than 15%)Wording
Conditional
How definitive the wording is.This transaction
Share acquisition (making the company a wholly owned subsidiary)CounterpartyOzhiba Ichiro (尾芝一郎), 3 other individual shareholders
Disclosing companyWOLVES HAND Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
CRO (Contract Research Organization) business and SMO (Site Management Organization) business
Location Chiyoda-ku, TokyoShare capital ¥34.852 millionDate of incorporation 30 January 2007
Net Sales¥283.987 million (fiscal year ending March 2026)
Operating profit¥91.578 million (fiscal year ending March 2026)
Net income for the current fiscal year¥106.080 million (fiscal year ending March 2026)
Net assetsNegative ¥12.024 million (fiscal year ending March 2026)
Consideration and expenses
Acquisition priceNot disclosed at the request of the counterparty
Impact on Business Performance
The impact is currently under review. If any matter requiring disclosure arises, it will be announced promptly.
Procedures and assumptions
Valuation methodologyValuation of the share value using methods including the DCF method, and legal and financial due diligence
| Item | Details |
|---|---|
| Transaction name | Share acquisition (making the company a wholly owned subsidiary) |
| Counterparty name | Ozhiba Ichiro (尾芝一郎), 3 other individual shareholders |
| Name of the Subject Company | メディトリックス株式会社 |
| Business Description of the Subject Company | CRO (Contract Research Organization) business and SMO (Site Management Organization) business |
| Location of the Subject Company | Chiyoda-ku, Tokyo |
| Capital Stock of the Subject Company | ¥34.852 million |
| Date of Establishment of the Subject Company | 30 January 2007 |
| Net Sales of the Subject Company | ¥283.987 million (fiscal year ending March 2026) |
| Operating Profit of the Subject Company | ¥91.578 million (fiscal year ending March 2026) |
| Net Income of the Subject Company | ¥106.080 million (fiscal year ending March 2026) |
| Net Assets of the Subject Company | Negative ¥12.024 million (fiscal year ending March 2026) |
| Acquisition price | Not disclosed at the request of the counterparty |
| Number of shares acquired | 1,469 shares (number of voting rights: 1,469) |
| Voting rights ownership percentage | Before 0.0％ → after 100.0％ |
| Impact on Business Performance | The impact is currently under review. If any matter requiring disclosure arises, it will be announced promptly. |
| Date of board resolution | 1 July 2026 |
| Contract Date | 3 July 2026 (scheduled) |
| Execution Date / Effective Date | 15 July 2026 (scheduled) |
| Valuation methodology | Valuation of the share value using methods including the DCF method, and legal and financial due diligence |
Items this document does not state (13)
Expenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Independent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To incorporate メディトリックス株式会社’s expertise in clinical research support, clinical trial operations, and data management, and establish an integrated structure covering the process from the clinical application and commercialization of R&D results through their implementation in society.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.